Drug Trial Radar · NCT06238635
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Mar 11, 2024
Primary completion
Dec 1, 2026
Study completion Jul 15, 2027
Sponsor
- Lead sponsor
- Meghan SheaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GlaxoSmithKline
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Conditions
- Cervical Cancer
- Advanced Cervical Carcinoma
- Metastatic Cervical Cancer
- Metastatic Cervical Carcinoma
- Recurrent Cervical Carcinoma
Interventions
DostarlimabDrug
Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
CobolimabDrug
Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Based on irRECISTTime frame: Up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.